BIOADAPTIVES, INC. (BDPT)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-15

Key Insights

Complex capital structure with multiple series of preferred stock (A, B, C, D) and convertible notes indicates significant dilution risk for common shareholders and suggests the company has relied heavily on preferred equity financing.
Presence of convertible notes originated across multiple years (2018, 2024, 2025) with recent November 2024 and 2025 issuances suggests ongoing liquidity needs and potential near-term conversion pressure that could further dilute common stock.
The filing contains multiple related-party transactions and executive compensation arrangements (Director, CEO, Employment Agreement members) that warrant careful review for potential conflicts of interest and fairness to minority shareholders.
Fair value measurements indicate use of Level 3 inputs (unobservable market data), suggesting significant uncertainty in valuation of assets and liabilities and potential for material adjustments in future periods.

Insider Trading Filed: 2026-05-05

Key Insights

Director Mark P. Frissora received 4,808 shares of Series D Convertible Preferred Stock on 05/01/2026 as board compensation, demonstrating continued director engagement and alignment with the company.
The preferred shares convert to 480,800 common shares at a 100:1 ratio but are subject to a 4.9% beneficial ownership limitation, indicating anti-dilution protections are in place for the company.
Conversion is restricted for six months from issuance (until 11/01/2026) except in liquidation events, suggesting the company has structured vesting to retain insider commitment through mid-November 2026.
The preferred shares carry 100 votes per share without ownership limitations for voting purposes, granting Frissora significant voting power (480,800 votes) despite the conversion cap.

Annual Report Filed: 2026-04-14

Key Insights

The company has experienced a significant increase in revenue over the past fiscal year, growing from $89 million to $1.25 billion, indicating strong market demand for its products.
The company's net income has remained stable at $8.2 million and $12 million in the last two fiscal years, suggesting efficient cost management and profitability.
The company has raised substantial capital through the issuance of various preferred stock series and convertible notes, totaling $66 million, which could be used to fund growth initiatives and expansion.

Insider Trading Filed: 2026-03-03

Key Insights

The reporting person, Mark P. Frissora, has acquired 2,578 shares of Series D Convertible Preferred Stock of BioAdaptives, Inc. (BDPT), which are convertible into 257,800 shares of common stock.
The Series D Convertible Preferred Stock was issued as compensation for Frissora's board services, indicating his continued involvement and commitment to the company.
The convertible preferred shares have a 4.9% beneficial ownership limitation, which may limit Frissora's ability to exercise full control over the company.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.